608 related articles for article (PubMed ID: 25880008)
1. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
2. Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.
Shen T; Gao C; Zhang K; Siegal GP; Wei S
Hum Pathol; 2017 Dec; 70():70-76. PubMed ID: 29031733
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
4. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
5. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for male breast cancer: similarity to female counterparts.
Yu E; Stitt L; Vujovic O; Joseph K; Assouline A; Au J; Younus J; Perera F; Tai P
Anticancer Res; 2013 May; 33(5):2227-31. PubMed ID: 23645780
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
8. The Difference in Prognostic Outcomes Between
Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
10. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
Jimeno A; Amador ML; González-Cortijo L; Tornamira MV; Ropero S; Valentín V; Hornedo J; Cortés-Funes H; Colomer R
Cancer; 2004 May; 100(9):1833-42. PubMed ID: 15112263
[TBL] [Abstract][Full Text] [Related]
11. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
Chang E; Mougalian SS; Adelson KB; Young MR; Yu JB
Breast Cancer Res Treat; 2019 Jan; 173(1):209-216. PubMed ID: 30242577
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
14. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
15. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
16. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Hanrahan EO; Broglio KR; Buzdar AU; Theriault RL; Valero V; Cristofanilli M; Yin G; Kau SW; Hortobagyi GN; Rivera E
Cancer; 2005 Sep; 104(6):1158-71. PubMed ID: 16047352
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
18. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
19. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival.
López-Guerrero JA; Llombart-Cussac A; Noguera R; Navarro S; Pellin A; Almenar S; Vazquez-Alvadalejo C; Llombart-Bosch A
Int J Cancer; 2006 Apr; 118(7):1743-9. PubMed ID: 16217770
[TBL] [Abstract][Full Text] [Related]
20. Survival differences among women with de novo stage IV and relapsed breast cancer.
Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
